These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34104829)

  • 1. Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy.
    Kasi A; Allen J; Mehta K; Dandawate P; Saha S; Bossmann S; Anant S; Sun W
    J Clin Transl Res; 2021 Apr; 7(2):257-262. PubMed ID: 34104829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: A Real-life Experience and Outcome from a Tertiary Care Centre.
    Yasmeen S; Arshad F; Shaukat S; Badar F; Kazmi SAS; Ahmad U
    J Cancer Allied Spec; 2021; 7(2):e409. PubMed ID: 37197218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Clark JW; Jiang W; Yeap BY; Drapek LC; Ly L; Baglini CV; Blaszkowsky LS; Ferrone CR; Parikh AR; Weekes CD; Nipp RD; Kwak EL; Allen JN; Corcoran RB; Ting DT; Faris JE; Zhu AX; Goyal L; Berger DL; Qadan M; Lillemoe KD; Talele N; Jain RK; DeLaney TF; Duda DG; Boucher Y; Fernández-Del Castillo C; Hong TS
    JAMA Oncol; 2019 Jul; 5(7):1020-1027. PubMed ID: 31145418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.
    Cavanna L; Stroppa EM; Citterio C; Mordenti P; Di Nunzio C; Peveri S; Orlandi E; Vecchia S
    Onco Targets Ther; 2019; 12():3077-3085. PubMed ID: 31118666
    [No Abstract]   [Full Text] [Related]  

  • 7. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
    JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.
    de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
    J Gastrointest Oncol; 2018 Oct; 9(5):806-819. PubMed ID: 30505579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.
    Zhang B; Zhou F; Hong J; Ng DM; Yang T; Zhou X; Jin J; Zhou F; Chen P; Xu Y
    World J Surg Oncol; 2021 Jun; 19(1):182. PubMed ID: 34154596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
    Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
    Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma.
    Chapman BC; Gleisner A; Rigg D; Messersmith W; Paniccia A; Meguid C; Gajdos C; McCarter MD; Schulick RD; Edil BH
    JOP; 2018 Mar; 19(2):75-85. PubMed ID: 29950957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
    Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
    Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of SOXIRI
    Li X; Huang J; Wang F; Jiang Q; Huang L; Li S; Guo G
    Ther Adv Med Oncol; 2023; 15():17588359231186029. PubMed ID: 37435561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.
    de Jesus VHF; Camandaroba MPG; Calsavara VF; Riechelmann RP
    Ther Adv Med Oncol; 2020; 12():1758835920905408. PubMed ID: 32165927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer.
    Ai D; Guan Y; Liu XJ; Zhang CF; Wang P; Liang HL; Guo QS
    Onco Targets Ther; 2016; 9():5693-5698. PubMed ID: 27695347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
    Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
    Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.